Vascular marker expression during the development of various types of gynaecological malignancy

Tumor Biology

Volumn 35, Issue 11, 2014, Pages 11229-11235

  Urban, Peter ^a   Rabajdova, Miroslava Bilecova ^a   Varga, Jan ^a   Kruzliak, Peter ^b   Fialkovicova, Viera ^a   Durovcova, Eva ^a   Marekova, Maria ^a  

^a P J AFÁRIK UNIVERSITY   (Slovakia)

^b ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

Author keywords

Death receptor; Gene expression; Ovarian cancer; Vascular markers

Indexed keywords

GPM6B PROTEIN, HUMAN; MEMBRANE PROTEIN; MESSENGER RNA; NERVE PROTEIN; TNFRSF21 PROTEIN, HUMAN; TUMOR MARKER; TUMOR NECROSIS FACTOR RECEPTOR;

CASE CONTROL STUDY; COMPARATIVE STUDY; FEMALE; FOLLOW UP; GENETICS; GENITAL NEOPLASMS, FEMALE; HUMAN; METABOLISM; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

BLOTTING, WESTERN; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; GENITAL NEOPLASMS, FEMALE; HUMANS; MEMBRANE GLYCOPROTEINS; NERVE TISSUE PROTEINS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, TUMOR NECROSIS FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 84927786802     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-014-2447-2     Document Type: Article

References (24)

1. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46(4):765–81.
2. Pleško I., Hlava P., Chakamen S. Cancer incidence in the Slovak Republic 2007. NCR SR, NHIC. 2012; 1–138.
3. Seaman S, Stevens J, Yang MY, Logsdon D, Graff-Cherry C, St CB. Genes that distinguish physiological and pathological angiogenesis. Cancer Cell. 2007;11:539–54.
4. MacFadyen JR, Haworth O, Roberston D, Hardie D, Webster MT, Morris HR, et al. Endosialin (TEM1, CD248) is a marker of stromal fibroblasts and is not selectively expressed on tumour endothelium. FEBS Lett. 2005;579:2569–75.
5. Coneja-Garcia J, Buckanovich R, Benencia F, Courreges MC, Rubin S, Carroll R, et al. Vascular leukocytes contribute to tumor vascularization. Blood. 2005;105(2):679–81.
6. Upson K, Allison KH, Reed SD, Jordan CD, Newton KM, Swisher EM, et al. Biomarkers of progestin therapy resistance and endometrial hyperplasia progression. Am J Obstet Gynecol. 2012;207(1):1–8.
7. Combes P, Bonnet-Dupeyron MN, Gauthier-Barichard F, Schiffmann R, Bertinni E. PLP1 and GPM6B intragenic copy number analysis by MAPH in 262 patients with hypomyelinating leukodystrophies, identification of one partial triplication and two partial deletions of PLP1. Neurogenetics. 2006;7(1):31–7.
8. Lönneborg A, Jorgen A, Dumeaux V, Børresen-Dale AL. Found in transcription: gene expression and other novel blood biomarkers for the early detection of breast cancer. Expert Rev Anticancer Ther. 2009;9(8):1115–23.
9. Guicciardi ME, Gores GJ. Life and death by death receptors. FASEB J. 2009;23(6):1625–37.
10. DeRosa DC, Ryan PJ, Okragly A, Witcher DR, Benschop RJ. Tumor-derived death receptor 6 modulates dendritic cell development. Cancer Immunol Immunother. 2008;57(6):777–87.
11. Benschop R, Wei T, Na S. Tumor necrosis factor receptor superfamily member 21: TNFR-related death receptor-6, DR6. Adv Exp Med Biol. 2009;647:186–94.
12. Daniels MS. Genetic testing by cancer site: uterus. Cancer J. 2012;18(4):338–42.
13. Buckanovich RJ, Sasaroli D, O’Brien-Jenkins A, Botbyl J, Hammond R, Katsaros D. Tumor vascular proteins as biomarkers in ovarian cancer. J Clin Oncol. 2007;25:852–61.
14. Croce CM. Molecular origins of cancer, oncogenes and cancer. New England J Medicine. 2008;358:502–11.
15. Yang K, Mooney C, Spahlinger G, Schuetze S, Arias-Pulido H, Verschraegen C, et al. DR6 as a diagnostic and predictive biomarker in adult sarcoma. PLoS One. 2012;7:36525.
16. Fjorback AW, Müller HK, Wiborg O. Membrane glycoprotein M6B interacts with the human serotonin transporter. J Mol Neurosci. 2009;37:191–200.
17. St Croix B, Rago C, Velculescu V, Romans KE, Montgomery E, Lal A, et al. Genes expressed in human tumor endothelium. Science. 2000;289:1121–2.
18. Bedkowska GE, Lawicki S, Szmitkowski M. Tumor markers useful in the diagnostic and monitoring of endometrial and cervical cancer. Postupy higieny i medycyny doświadczalnej. 2007;61:122–8.
19. Wang ZC, Birkbak NJ, Culhane AC, Drapkin R, Fatima A, Tian R, et al. Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome. Clin Cancer Res. 2012;18(20):1–10.
20. Li F, Liu Q, Han Y, Wu B, Yin H. Sperm protein 17 is highly expressed in endometrial and cervical cancers. BMG Cancer. 2010;16(10):429.
21. Wang F, Fischman D. Tumor vascular proteins: groundbreaking as potential new ovarian cancer biomarkers. Expert Review of Obstetrics and Gynecology. 2007;2(5):553–6.
22. Huang GS, Gebb JS, Einstein MH, Shahabi S, Novetsky AP, Goldberg GL. Accuracy of preoperative endometrial sampling for the detection of high-grade endometrial tumors. Am J Obstet Gynecol. 2007;196(3):1–5.
23. Sasarolli D, Gimothy P, Pahtak HB. Novel surface targets and serum biomarkers from the ovarian cancer vasculature. Cancer Biol Ther. 2011;12(3):169–80.
24. Berois N, Blanc E, Ripoche H, Mergui X, Trajtenberg F, Cantais S, et al. Cancer diagnostic, ppGalNAc-T13, a new molecular marker of bone marrow involvement in neuroblastoma. Clin Chem. 2006;52(9):1701–12.